retatrutide trial news New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Phase 2 Trial of Retatrutide

What is Saxenda

While semaglutide is a single agonist (GLP-1 agonist), retatrutide is a triple agonist meaning it targets three hormones: GLP-1, GIP, and GCG

*One per box with active subscription

AnnualSave 47% Discounted annual rate Access to all articles (web + app) Ad-free exclusive newsletters Commenting Access Daily crossword Sneak peek of launches & events Monthly Access to all articles (web + app) Ad-free exclusive newsletters Commenting Access Daily crossword Sneak peek of launches & events Ad-Free Premium ad-free reading Access to all articles (web + app) Ad-free exclusive newsletters Commenting Access Daily crossword Sneak peek of launches & events Looks like you already have a subscription

You will understand the dual GIP and GLP-1 mechanism at a level most users never reach, the specific science behind B12 inclusion, every major compounded formulation available, the escalation schedule that produces results while minimizing side effects, storage requirements that protect potency, and the emerging microdosing protocols that go beyond weight loss entirely